Mirum Pharmaceuticals Highlights Preliminary Sales Estimates
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is excited to share preliminary and unaudited estimates for its full-year 2024 net product sales and year-end cash position. This announcement follows notable achievements and corporate advancements that underpin the company’s dedication to addressing unmet medical needs.
CEO Insights on Company Progress
Chris Peetz, the CEO of Mirum, reflected on the company's success over the past year, stating that 2024 has represented a pivotal period as they enhanced their commercial operations and hit critical development targets. The progress in treating cholestatic diseases stands out, especially with the label expansion for LIVMARLI and the positive developments concerning volixibat for PSC and PBC.
Ongoing Developments in Rare Diseases
Mirum bolstered its initiatives in rare genetic neurology by submitting a New Drug Application (NDA) for chenodiol and securing the in-licensing of MRM-3379, aimed at treating Fragile X syndrome. Mirum's commitment to commercial excellence in the ultra-rare disease market is evident as they continue to showcase a robust pipeline with growth opportunities.
Financial Guidance for 2025
Looking ahead, the company is optimistic about continued revenue expansion. The guidance for 2025 anticipates approximately $420 million to $435 million in global net product sales, signaling a strong trajectory for cash flow from operations.
Key Milestones Ahead
Significant trials and data releases are on the horizon:
- Completion of enrollment for the VISTAS study in PSC expected in mid-2025, with topline data anticipated in 2026.
- The VANTAGE study in PBC is projected to finalize enrollment in 2026.
- LIVMARLI's EXPAND Phase 3 study is expected to complete enrollment within the same timeframe.
- Chenodiol's PDUFA date for CTX is set for March 28, 2025, marking a critical point in regulatory efforts.
- A Phase 2 study for MRM-3379 in Fragile X Syndrome is slated to kick off in 2025.
2024 Business Highlights
Throughout 2024, Mirum demonstrated leadership in the rare disease market, particularly in hepatology and genetic neurology:
Sales Performance
Estimated net product sales for LIVMARLI are around $213 million, while CHOLBAM and CHENODAL products are projected to generate approximately $123 million in sales. In Q4 2024, total estimated product sales hover near $99 million, showcasing a solid finish to the year.
Geographical Expansion
Mirum has extended its global presence with access in 30 countries, successfully negotiating reimbursements and launching products in key European markets, paving the way for broader access to innovative therapies.
Regulatory Achievements
The company has made significant strides in expanding its leadership across rare diseases, with several regulatory milestones:
Positive Study Outcomes
Recent interim results from volixibat studies in PSC and PBC demonstrated efficacy and safety, propelling the drug’s profile into the spotlight. Notably, volixibat gained breakthrough therapy designation by the FDA for cholestatic pruritus treatment, enhancing its regulatory clout.
Approval Advances
LIVMARLI's approval by the FDA for treating cholestatic pruritus in PFIC patients aged 12 months and older marks a salient accomplishment for Mirum, which is also gaining approval in Europe for younger patients. The initiation of the LIVMARLI EXPAND Phase 3 study signifies a proactive approach to addressing patient needs in rare cholestatic conditions.
Mirum's Financial Robustness
As of late 2024, the company maintains a solid financial footing, with an estimated cash, cash equivalents, and investments worth around $287 million. This slight increase from the previous year underscores stable operational performance.
Leadership Developments
In a move to elevate its executive team, Mirum recently appointed Dr. Joanne Quan as Chief Medical Officer, reflecting the company’s commitment to enhancing its strategic capabilities.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is committed to transforming the landscape of rare disease treatments for all ages. The company has three approved products: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid), and CHENODAL® (chenodiol). Through strategic initiatives and a focus on patient-centric outcomes, Mirum aims to provide groundbreaking therapies for patients with rare and complex conditions.
Frequently Asked Questions
What are the sales estimates for LIVMARLI in 2024?
Estimated sales for LIVMARLI in 2024 are about $213 million.
What is the main focus of Mirum Pharmaceuticals?
Mirum focuses on developing treatments for rare diseases affecting children and adults.
When is the PDUFA date for chenodiol?
The PDUFA date for chenodiol in CTX is March 28, 2025.
What major studies are anticipated in the coming years?
Key studies include VISTAS, VANTAGE, and the LIVMARLI EXPAND Phase 3 study.
Who is the newly appointed Chief Medical Officer?
Dr. Joanne Quan has been appointed as the Chief Medical Officer at Mirum.
